WALVAX(SZ:300142) Xin Lang Zheng Quan·2025-10-21 06:07Core Viewpoint - Watson Bio's stock has shown fluctuations with a recent increase of 2.11%, while the company faces a decline in revenue and profit for the first half of 2025 [1][2]. Financial Performance - As of June 30, 2025, Watson Bio reported a revenue of 1.154 billion yuan, a year-on-year decrease of 19.47% [2]. - The net profit attributable to shareholders was 43.16 million yuan, down 74.69% compared to the previous year [2]. - Year-to-date, the stock price has decreased by 3.98%, with a recent 5-day increase of 1.76% and a 20-day decrease of 5.93% [1]. Shareholder Information - The number of shareholders increased to 117,300, up 3.73% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 3.88% to 13,268 shares [2]. - The top circulating shareholder is E Fund's ChiNext ETF, holding 40.27 million shares, a decrease of 1.0618 million shares from the previous period [3]. Company Overview - Watson Bio, established on January 16, 2001, and listed on November 12, 2010, specializes in the research, production, and sales of vaccine products [1]. - The company's revenue composition includes 94.82% from self-developed vaccines, 4.67% from intermediate products, and 0.26% from other services [1]. - The company operates within the pharmaceutical and biological industry, specifically in the vaccine sector [1].